Patent 11084865

Assignment history

Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.

Active provider: Google · gemini-2.5-flash

Ownership chain (1)

Asserters network →

Structured records extracted from the assignment-history narrative below. Each entity links to its full ownership-network profile.

  1. 2020-07-08 · reel 051939/0634 · Assignment

    DIX, DANIEL; GRAHAM, KENNETH S.; FURFINE, ERIC; FRYE, KELLYREGENERON PHARMACEUTICALS, INC.

    internal reorg

Assignment history

Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.

✓ Generated

Inventors

  • Eric Furfine (Regeneron Pharmaceuticals Inc)
  • Daniel Dix (Regeneron Pharmaceuticals Inc)
  • Kenneth Graham (Regeneron Pharmaceuticals Inc)
  • Kelly Frye (Regeneron Pharmaceuticals Inc)

Original assignee

Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc. is a biotechnology company that invents, develops, manufactures, and commercializes medicines. They ship products embodying the claims, specifically Eylea (aflibercept), which is a VEGF antagonist formulation for intravitreal administration. Regeneron is currently an operating company.

Assignment timeline

  • 2020-07-08 (executed) / recorded 2020-07-08 — Reel 051939/0634
    • Conveyance: Assignment
    • Assignor: DIX, DANIEL; GRAHAM, KENNETH S.; FURFINE, ERIC; FRYE, KELLY
    • Assignee: REGENERON PHARMACEUTICALS, INC.
    • Correspondent: REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NEW YORK, UNITED STATES, 10591-6707.
    • Context: Internal reorg (assignment from individual inventors to the corporate entity).

Timeline diagram

timeline
    title Ownership of US 11084865
    2006 : Priority date
    2020 : Application filed
    2020 : Inventors assigned to Regeneron
    2021 : Issued

NPE / troll-pattern signals

  1. Shell-entity transfer — not present
  2. Known asserter in the chain — not present
  3. Repeat correspondent across the chain — not present
  4. Cascading transfers — not present
  5. Pre-litigation transfer — not present
  6. Bankruptcy fire-sale — not present
  7. Privateering — not present
  8. Defensive aggregator (anti-NPE) — not present

Verdict

Operating-company assertion
The patent was assigned from the individual inventors to Regeneron Pharmaceuticals Inc., a known operating company that commercializes products embodying the claims. There are no other assignments on record, indicating the patent remains with the original operating company.
USPTO Assignment Center search for US11084865

Generated 5/20/2026, 12:47:06 AM